香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 大中華金融控股有限公司 G REATER CHINA FINANCIAL HOLDINGS LIMITED 茲提述大中華金融控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」） 日期為二零二四年八月二十一日、二零二四年八月三十日、二零二四年九月十七 日及二零二五年四月八日之公佈，內容有關（其中包括）上市科就香港聯合交易所 有限公司（「聯交所」）證券上市規則（「上市規則」）第13.24條作出的決定及聯交 所就本公司股份（「股份」）恢復買賣而載列的復牌指引（「復牌指引」）；及本公司 日期為二零二四年十一月二十九日、二零二五年一月二十二日、二零二五年二月 二十八日、二零二五年五月二十八日及二零二五年八月二十九日之公佈，內容有 關復牌進展之季度更新（統稱「季度更新公佈」）。除另有說明外，本公佈所用詞彙 與季度更新公佈所界定者具有相同涵義。 本公司謹此提供以下有關復牌進展及預期時間表之資料： 復牌指引 有關 ...

Group 1 - The core point of the article is the announcement by two major South Korean petrochemical companies, Lotte Chemical and HD Hyundai Chemical, regarding their application to the government for approval of their petrochemical business integration plan, aimed at enhancing industry competitiveness and optimizing industrial layout [1][2] - The integration plan specifically addresses the structural overcapacity issue in the naphtha cracking center (NCC) within the domestic petrochemical industry, with Lotte Chemical planning to divest its NCC operations at the Daesan Industrial Complex and merge them with HD Hyundai Chemical [1] - The restructuring involves a total ethylene production capacity of 1.95 million tons per year, with Lotte Chemical's Daesan plant contributing 1.1 million tons and HD Hyundai Chemical contributing 850,000 tons [1] Group 2 - The South Korean petrochemical industry is facing a severe survival crisis due to continuous new capacity additions leading to oversupply and significant profit margin declines [2] - In response to the crisis, ten major South Korean petrochemical companies signed an agreement in August to restructure their businesses, which includes substantial capacity reductions to fundamentally improve competitiveness [2]

11月24日，华锋股份披露筹划易主并停牌的公告。公告显示，公司于当日午间确认接盘方为陈运， 陈运拟取得公司控制权。公司股票自11月24日起停牌。 华锋股份表示，截至公告披露日，谭帼英持有公司约4280.07万股，占公司总股本的20.14%；具体 收购方案以双方签署的正式股份转让协议为准，本次事项仍处于意向阶段，具有不确定性。 公告称，陈运或其控制的第三方拟一次性或分期收购谭帼英持有的公司股权，并可能通过表决权委 托方式取得公司控制权。若交易最终完成，公司控股股东及实际控制人将发生变更。 公开资料显示，陈运（1975年9月生）曾为合力泰与三利谱两家公司联合创始人并担任董事、副总 经理职务，2018年自合力泰退出。合力泰主要为消费电子、智能家居等领域提供液晶触控显示模组 与OLED触显模组等解决方案。三利谱自2017年上市，主要从事偏光片产品的研发与生产。 华锋在公告中提示，本次签署的股权转让意向协议仅为初步意向，交易存在不确定性。市场关注点 在于，若控制权变更最终实现，华锋股份是否会出现业务重组或向偏光片/光学材料领域倾斜，以及 对原有新能源汽车与电极箔业务的影响。（集邦Display整理） 【集邦Displa ...

格隆汇11月21日｜据彭博引述一份员工内部备忘显示，汇丰控股正重组交易业务，主攻债务融资。其 中，10国集团利率交易部门将与外汇、新兴市场利率及商品部门合并，成为新的全球宏观交易部门；衍 生工具结算服务将并入环球股票团队。备忘录表明，所有全球债券市场余下业务，包括高息、投资级债 券交易及新兴市场信贷业务等，都会归入环球信贷及融资部门管辖，与投资银行及承销团队紧密合作， 期望提升客户联系程度及提升营运效率。报道引述消息称，在汇控工作30年的环球债市主管Mehmet Mazi将在重组后离职。 ...

Core Insights - Gabriel Group demonstrated solid improvement in key financial figures for the 2024/25 financial year, with revenue growth and significant profit improvement in continuing operations, while restructuring efforts are ongoing in the discontinued operations in Mexico [1][2][3]. Financial Performance - In the 2024/25 financial year, Gabriel Group reported revenue of DKK 902.7 million, a slight decrease from DKK 912.3 million in 2023/24. However, operating profit (EBIT) increased to DKK 28.2 million from DKK 10.9 million in the previous year [2]. - Continuing operations generated revenue of DKK 516.0 million, up from DKK 483.5 million, reflecting a growth of DKK 32.5 million (7%). Operating profit (EBIT) for continuing operations was DKK 44.1 million, compared to DKK 19.7 million in the prior year [6][8]. - The operating profit margin (EBIT margin) improved to 8.5% from 4.1%, and profit before tax rose to DKK 33.8 million from DKK 4.0 million. Profit after tax also improved to DKK 24.8 million from a loss of DKK 1.5 million [8]. Business Operations - The strong performance in continuing operations was attributed to growth in the global textile business across North America, Europe, and Asia, alongside stable revenue from the SampleMaster business unit [6]. - The FurnMaster business unit in Mexico is undergoing restructuring, which has negatively impacted its results. The company plans to divest the FurnMaster business units, which are classified as discontinued activities, with expectations for a sale to be completed in the financial year 2025/26 [4][10]. Future Expectations - Management anticipates that challenging market conditions will persist in the 2025/26 financial year, primarily due to ongoing geopolitical risks. However, they expect the trend of revenue and profit growth in continuing operations to continue [10]. - Revenue from continuing operations is projected to be between DKK 510–550 million, with a primary profit (EBIT) expected in the range of DKK 40–50 million for the upcoming financial year [11].

Core Viewpoint - Panasonic Holdings is selling an 80% stake in its wholly-owned subsidiary Panasonic Housing Solutions to YKK Corporation, while retaining a 20% stake, as part of its organizational restructuring and business reform efforts [1][2]. Group 1: Company Overview - Panasonic Housing Solutions (PHS) is closely linked with Panasonic Housing Technology (Hangzhou) Co., Ltd., which focuses on residential equipment and building materials manufacturing and sales [2]. - PHS is categorized as a "restructuring business" under Panasonic's comprehensive organizational adjustments initiated by CEO Yuki Kusumi [2]. Group 2: Acquisition Details - The acquisition by YKK, a leading zipper manufacturer, aims to combine the strengths of both companies to establish a leadership position in the building materials and residential equipment market [3]. - The total business scale of YKK AP and PHS is approximately 1 trillion yen (about 456.79 billion RMB), providing a wide range of products necessary for construction [3]. Group 3: Future Plans - The transfer agreement is expected to be finalized by the end of March 2026, with operations under the new structure starting in April 2026 [3]. - Panasonic aims to leverage its brand and technological advantages in the Chinese market, focusing on modular reconstruction of space value and developing business content tailored to local needs [3]. - The long-term goal is to achieve a combined sales target of 1.5 trillion yen (approximately 685.19 billion RMB) by 2035 [3].

和泓服务(06093)公布，于2025年11月14日(联交所交易时段结束后)，公司的间接全资附属和泓福瑞盈 (贵州)信息咨询有限公司拟向中山市福润物业服务有限公司出售中山市中正物业管理有限公司51%股 权，代价为人民币787.74万元。 公告称，出售目标公司51%股权是一项经过策略性考虑的决定，旨在加强集团的营运重点及财务灵活 性。透过出售目标公司的权益，集团得以精简其业务组合，更专注于其余物业管理组合，该等业务的收 入稳步增长，市场占有率不断上升。 ...

Financial Data and Key Metrics Changes - Third quarter revenue was $1.6 billion, with adjusted EBITDA of $518 million, representing an adjusted EBITDA margin of 32.3% [13][30] - The company is lowering its full-year revenue guidance to $6.2 billion-$6.25 billion, reflecting a year-over-year nominal decline of 3.2%-2.4% [33] - Adjusted gross margin for the third quarter was 60.3%, down from 61.7% in the same quarter of 2024, primarily due to pricing pressure and unfavorable product mix [29][30] Business Line Data and Key Metrics Changes - Women's health franchise revenue declined 4% in the third quarter compared to the same period in 2024, with a 9% decline in Nexplanon sales [17] - Global Nexplanon sales were $223 million in the third quarter, with a 50% decline in the U.S. and a 7% growth internationally [17][18] - The fertility business was flat in the third quarter but up 13% year-to-date, with expectations of high single-digit growth for the full year [19] - Hadlima, a biosimilar, saw a 63% increase in sales year-to-date, contributing significantly to the biosimilars segment [21] Market Data and Key Metrics Changes - The U.S. market for Nexplanon faced challenges due to unfavorable policy changes impacting budget-constrained public segments [17][18] - The respiratory business is experiencing declines, particularly in Singulair and Dulera, due to competitive pressures and mandatory price reductions [24][25] Company Strategy and Development Direction - The company remains focused on deleveraging, driving cost savings, and achieving revenue growth [12][38] - A definitive agreement was made to divest the JADA system for $440 million, which will help in faster deleveraging [20] - The company is committed to enhancing operational performance and aligning resources to strategic priorities [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating current headwinds and emphasized the importance of operational excellence [10][38] - The company anticipates that the discontinuation of certain sales practices will have a significant impact on future revenue [15][19] - Management expects Nexplanon sales to be down mid to high single digits for the full year in the U.S. but anticipates international growth [18][19] Other Important Information - The independent internal investigation regarding improper sales practices has concluded, and remediation efforts are underway [9][48] - The company is not planning any additional divestitures at this time but will continue to evaluate its portfolio strategically [40] Q&A Session Summary Question: Are there opportunities for additional divestitures within the portfolio? - The company is constantly evaluating its assets but has no definitive plans for further divestitures at this time [40] Question: When should growth inflection for Vtama be expected? - Significant strides have been made to improve access, and 2026 is seen as a key year for evaluating growth trajectory [41] Question: Can you elaborate on the pressure on the respiratory business? - The respiratory business is expected to continue facing challenges due to competitive pressures and mandatory price reductions [42][43] Question: What are the expectations for Denosumab and its impact on future revenue? - The company is excited about Denosumab's launch and anticipates it will contribute positively to the biosimilars segment [54] Question: How is the CEO search progressing? - The search committee is actively working to find a permanent CEO, with no strategic changes anticipated in the interim [51]

Core Viewpoint - The company, Ocean Group, has announced the sale of a 60% stake in its subsidiary, East Shack Limited, to New Vision International Ltd for £313,415 (approximately HKD 3.15 million), effective November 20, 2024. This divestment will result in the company no longer holding any equity in the target company, which will cease to be a subsidiary, thus removing its financial performance from the group's consolidated financial statements [1]. Summary by Sections - The sale agreement involves WTS 2020 Limited (the seller) and New Vision International Ltd (the buyer) [1]. - The decision to sell was influenced by strategic differences in operational philosophy and management style between the company and other shareholders of the target group [1]. - The divestment is part of a broader restructuring of the company's retail business segment, allowing for the reallocation of resources to other existing opportunities [1].

Financial Data and Key Metrics Changes - Net sales for Q1 fiscal 2026 were $366 million, a 2% decline compared to Q1 fiscal 2025 [5][10] - Gross margin rate improved to 7.9%, a 160 basis point increase from 6.3% in the same period last year [10] - Adjusted income for Q1 was $17.5 million, or 4.8% of net sales, compared to $12.6 million, or 3.4% of net sales last year [11][12] - Adjusted net income was $12.3 million, or $0.49 per diluted share, up from $5.5 million, or $0.22 per diluted share last year [12][13] - Cash and cash equivalents at the end of Q1 were $75.7 million, with cash generated from operations at $8.1 million [13][15] Business Line Data and Key Metrics Changes - Medical sales were $102 million, up 13% year-over-year, accounting for 28% of total revenue [5][6] - Automotive sales were $164 million, down 10% year-over-year, representing 45% of total sales [7] - Industrial sales totaled $100 million, a 1% decrease compared to Q1 last year, making up 27% of total sales [7][8] Market Data and Key Metrics Changes - Medical sales growth was driven by strong performance in North America, Asia, and Europe [5][6] - Automotive sales decline was primarily due to lower sales in North America and Asia, partially offset by growth in Europe [7] - Industrial business saw a decline in North America due to softening demand for HVAC, while Asia reported strong sales growth [8] Company Strategy and Development Direction - The company aims to expand its capabilities in the medical sector, focusing on higher-level assemblies and finished medical devices [6][18] - A tuck-in acquisition strategy is being pursued to add new end markets and manufacturing capabilities [18] - The company is committed to returning to profitable growth, particularly in the medical space, while managing costs and improving margins [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to profitable top-line growth next year and reiterated guidance for fiscal 2026 [4][16] - The company is monitoring the evolving global tariff landscape and expects to recover tariff costs by passing them on to customers [8][9] - Management highlighted the importance of maintaining a strong balance sheet while preparing for growth [43][44] Other Important Information - Cash conversion days improved to 83 days, representing the lowest level in over three years [13][14] - Capital expenditures in Q1 were $10.6 million, primarily for leasehold improvements and the new facility in Indianapolis [15][16] - The company has $14.8 million remaining on its share repurchase program [15] Q&A Session Summary Question: Will working capital increase as top-line growth resumes? - Management does not expect a significant increase in working capital as they have improved inventory management [21][22] Question: Is the current cash conversion days level stable? - Management aims for cash conversion days to remain in the low 80s as the business grows [23] Question: What are the expectations for EBITDA margins? - Management does not expect a deterioration in EBITDA margins and anticipates improvements as growth resumes [24] Question: What is the focus for potential acquisitions in the medical segment? - The company is exploring acquisitions in the medical CMO space, focusing on new technologies and geographies [28] Question: How does the pipeline of medical projects look for revenue growth? - The company has a strong pipeline of medical projects and expects to close several as the year progresses [37][38] Question: What is the outlook for the automotive segment? - Management anticipates continued pressure in the automotive market but remains strategically focused on high-visibility revenue [41] Question: How is the company balancing organic growth and potential acquisitions? - Management is focused on disciplined capital allocation and will consider acquisitions that enhance their CMO strategy [43][44] Question: What impact does accelerated depreciation have on the company? - Accelerated depreciation is beneficial, particularly regarding interest expense deductions [46]